Received: by rdfig.net (Wildcat! SMTP Router v7.0.454.5)
for FigueroaFamily@rdfig.net; Mon, 07 Aug 2017 20:08:41 -0500
Received: from NAM02-SN1-obe.outbound.protection.outlook.com ([40.92.5.50])
by rdfig.net (Wildcat! SMTP v7.0.454.5) with ESMTP
id 1039240203.10.5340; Mon, 07 Aug 2017 20:08:40 -0500
Received-SPF: pass (rdfig.net: domain of sfig01@hotmail.com
designates 40.92.5.50 as permitted sender)
receiver=rdfig.net;
client-ip=40.92.5.50;
envelope-from=sfig01@hotmail.com;
helo=nam02-sn1-obe.outbound.protection.outlook.com;
Authentication-Results: rdfig.net
reason=(smtp.client-ip=40.92.5.50;
smtp.helo=nam02-sn1-obe.outbound.protection.outlook.com);
spf=pass smtp.mailfrom=sfig01@hotmail.com;
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=hotmail.com;
s=selector1; h=From:Date:Subject:Message-ID:Content-Type:MIME-Version;
bh=Nr9FqrLTEZ2xzhcuJlhOqC/SQqW/bOMXg7sL89+4L1g=;
b=GZZ1izdzYwQlEvaO6UKER1ArQMZjV6lMxxQnhsuXaLeaAXhVu
oNV5WwLEsXCsu7fhTto7ehCY/v4P
s8rANWdAIgK4C6+8uzkQ+H1IDFPDeE3QW888qiDy6b4Iyj2Zm8y
wUtb+jseOIWOoLTyYL222jOSPHDS
gsNnl9LTDtOkPOX+IU5V8/OPCLV/uuzgV6s2i81Rkn7yrBDS2j+
572jeep22cYNtoakZuuFp+A6gDbb
M+mlD5O5JGiogljQoZ47pMovgDdzqpM+LA0QrppWBXpghNGsrCj
CDHUw+6d/2CfUt2uvzWcOWd9nLhE
cXUoh9ydPwFLMKx6dnvqgxfQnJ5w==
Received: from CY1NAM02FT043.eop-nam02.prod.protection.outlook.com
(10.152.74.56) by CY1NAM02HT166.eop-nam02.prod.protection.outlook.com
(10.152.75.144) with Microsoft SMTP Server (version=TLS1_2,
cipher=TLS_ECDHE_RSA_WITH_AES_256_CBC_SHA384_P384) id 15.1.1282.16; Tue, 8
Aug 2017 01:08:40 +0000
Received: from CY4PR10MB1718.namprd10.prod.outlook.com (10.152.74.51) by
CY1NAM02FT043.mail.protection.outlook.com (10.152.74.182) with Microsoft
SMTP
Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_128_CBC_SHA256_P256)
id
15.1.1304.16 via Frontend Transport; Tue, 8 Aug 2017 01:08:40 +0000
Received: from CY4PR10MB1718.namprd10.prod.outlook.com ([10.172.68.145]) by
CY4PR10MB1718.namprd10.prod.outlook.com ([10.172.68.145]) with mapi id
15.01.1320.018; Tue, 8 Aug 2017 01:08:40 +0000
From: Sharon Figueroa
To: "Figueroa Family (FigueroaFamily@rdfig.net)"
CC: "Sharon Figueroa - WORK (sfigueroa@excoresources.com)"
Subject: New Medicine spreadsheets - Mama
Thread-Topic: New Medicine spreadsheets - Mama
Thread-Index: AdMP4mcbXUbb157fRXGOMqOgZlEaYg==
Date: Tue, 8 Aug 2017 01:08:39 +0000
Message-ID:
com
>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach: yes
X-MS-TNEF-Correlator:
authentication-results: rdfig.net; dkim=none (message not signed)
header.d=none;rdfig.net; dmarc=none action=none header.from=hotmail.com;
x-incomingtopheadermarker:
OriginalChecksum:CC541B3305BA2A1417F16D2F1215D80754
A3246B160C17B9DE912149407BC9
0E;UpperCasedChecksum:51176D258317EB3E666CF1A75B9A2
365276EA190231EE6BB8392D48C7
66A564D;SizeAsReceived:7108;Count:44
x-tmn: [HHYPYYPnD5nZp4mlmt6jmMpulTsOMQml]
x-ms-publictraffictype: Email
x-microsoft-exchange-diagnostics:
1;CY1NAM02HT166;7:cG22RuA2DRjPcuSgWziy9UOLFzOfGNiI7
QRAUmkbHiVtyYt7dFM6yEjN4+Zpt
OW0dkCBcdWGtsU++WG7NbYimtBBo9QmwGmuMFPNAcEiAkxPNIxP
GM42qDD9RhYYA6/CSemrOWLdNmEi
+A75TeV2s8kmyN90v2x3TbNa3rnLizXjPlLzsZr/kS+Ujlz6yTh
e3jxReIUqrM9o6/2GN7lQvfaExkv
BW1iJybRMfZEdKwDNJDvi8JMJ5clQ7k1hujbefFvN3vlCSu3WEz
G+GLsM4oaCr9GGPDzlrIs+iGE0sw
C8EN7j/rgNStag2RBfsLwswlxhKhYwdpq1TQefZpxXDqfafQO95
9MD2ncPFR7lLnhGPyHoIihadbdsR
lb1SeYi297ZyoX7wP/J7MgEa+D1iqWU8icXwwZ2qp6e/r2juyit
9MLd3TgIYS2mmnlOswZAerKL9Q7g
V2fALQZH+Va5yaNKAJ4SfzZLiQw7zpGwcIcloJFZXdAmI9yLQ1i
OEwbsliW8qc+NfFJag/1nzOdyS7X
9qNK3tMHDEkf6h2BcaHO/DFwidhiafxraek35hGhldlgqqJvULg
Zixn97ZGneR9LVZ5TZwmocbEN+aY
HweDJYdZpPjTC7zhR0jGSEWHieXIFi5X8786hRw66FubYpG0N4a
5FUfplvEEsSN4FcB0n0PLv+D4kTg
5aDMRfC7moiCUeGLps/0OaAAdqSheDpCXpQ0+2Be3zYzGOMWGVH
k/Nf+doXS1doDS3SCS3aITjh+hRv
OLceYYo4uk5qrG90qg==
x-incomingheadercount: 44
x-eopattributedmessage: 0
x-forefront-antispam-report:
EFV:NLI;SFV:NSPM;SFS:(7070007)(98901004);DIR:OUT;SF
P:1901;SCL:1;SRVR:CY1NAM02HT
166;H:CY4PR10MB1718.namprd10.prod.outlook.com;FPR:;SPF:None;LANG:en;
x-ms-office365-filtering-correlation-id: 207bce8f-3d5e-4e47-c4cb-
08d4ddfa017b
x-microsoft-antispam:
UriScan:;BCL:0;PCL:0;RULEID:(300000500095)(30013500
0095)(300000501095)(30013530
0095)(22001)(300000502095)(300135100095)(3000005030
95)(300135400095)(2017020610
74)(5061506573)(5061507331)(1603103135)(20170313202
74)(2017031324274)(201703132
3274)(2017031322377)(1603101448)(1601125374)(170103
1045)(300000504095)(30013520
0095)(300000505095)(300135600095)(300000506095)(300
135500095);SRVR:CY1NAM02HT16
6;
x-ms-traffictypediagnostic: CY1NAM02HT166:
x-exchange-antispam-report-test: UriScan:(21748063052155);
x-exchange-antispam-report-cfa-test:
BCL:0;PCL:0;RULEID:(100000700101)(100105000095)(100
000701101)(100105300095)(100
000702101)(100105100095)(444000031);SRVR:CY1NAM02HT
166;BCL:0;PCL:0;RULEID:(1000
00800101)(100110000095)(100000801101)(100110300095)
(100000802101)(100110100095)
(100000803101)(100110400095)(100000804101)(10011020
0095)(100000805101)(10011050
0095);SRVR:CY1NAM02HT166;
x-forefront-prvs: 03932714EB
spamdiagnosticoutput: 1:99
spamdiagnosticmetadata: NSPM
Content-Type: multipart/mixed;
boundary="_005_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_"
MIME-Version: 1.0
X-OriginatorOrg: hotmail.com
X-MS-Exchange-CrossTenant-originalarrivaltime: 08 Aug 2017 01:08:40.0321
(UTC)
X-MS-Exchange-CrossTenant-fromentityheader: Internet
X-MS-Exchange-CrossTenant-id: 84df9e7f-e9f6-40af-b435-aaaaaaaaaaaa
X-MS-Exchange-Transport-CrossTenantHeadersStamped: CY1NAM02HT166
--_005_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_
Content-Type: multipart/alternative;
boundary="_000_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_"
--_000_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable
Attached are updated spreadsheets. Debbie took Mama to Dr. O today. Added=
37.5 mg capsule in the AM of Venlafaxine. Also has Macrobid antibiotic fo=
r chronic UTI. Lorazepam also is now given at noon - half a tablet in addi=
tion to what she already gets in the AM and PM. Supplements spreadsheet al=
so updated to add amino acids we added and to rearrange some to be given at=
noon. Let me know if there are any questions.
Sharon
--_000_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable
osoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http:=
//www.w3.org/TR/REC-html40">
>
Attached are updated spreadsheets. Debbie took=
Mama to Dr. O today. Added 37.5 mg capsule in the AM of Venlafaxine.=
Also has Macrobid antibiotic for chronic UTI. Lorazepam also i=
s now given at noon – half a tablet in addition to what
she already gets in the AM and PM. Supplements spreadsheet also upda=
ted to add amino acids we added and to rearrange some to be given at noon.&=
nbsp; Let me know if there are any questions. Sharon
--_000_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_--
--_005_CY4PR10MB1718AC549F6391C5F40BC8AED58A0CY4PR10MB1718namp_
Content-Type:
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet;
name="2017-08-07 Mama's RX Schedule.xlsx"
Content-Description: 2017-08-07 Mama's RX Schedule.xlsx
Content-Disposition: attachment;
filename="2017-08-07 Mama's RX Schedule.xlsx"; size=14488;
creation-date="Tue, 08 Aug 2017 01:05:23 GMT";
modification-date="Tue, 08 Aug 2017 01:04:40 GMT"
Content-Transfer-Encoding: base64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|
